Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Lenvatinib in High Risk Locally Advanced Cervix Cancer (EMBRACE High Risk)
NCT07368985Phase 2Not yet recruiting
- Start
- Mar 2026
- Primary completion
- Oct 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenvatinib in Cervical Cancer (CC). Planned start Mar 2026; status: not yet recruiting.
02
Drugs
lenvatinib
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT07368985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07368985.